The controversy over long-acting beta agonists: examining the evidence
- PMID: 17128539
- DOI: 10.3949/ccjm.73.11.973
The controversy over long-acting beta agonists: examining the evidence
Abstract
In the Salmeterol Multicenter Asthma Research Trial (SMART), patients receiving the long-acting beta agonist salmeterol--particularly African Americans--had a statistically significantly higher risk of fatal or potentially fatal asthma episodes. As a result, medications that contain salmeterol (Serevent, Advair) or formoterol (Foradil) carry a "black box warning." However, the benefits of these drugs continue to outweigh the risks, if they are used appropriately.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials